ArticleBMC medicine2025
Global, regional, and national burden of idiopathic epilepsy in older adults, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Global and Regional Burden of Refraction Disorders In Children, Adolescents and Young Adults from 1990 to 2021: Trends, Inequalities and Future Predictions with Machine Learning.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Article
- Global trends in epilepsy and the Chinese experience: Epidemiological transitions, underlying mechanisms, and integrated strategies (1990-2021).Neuroprotection (Chichester, England) · 2026Review
- Design and Simulation of Lamotrigine Intermittent Release from a Subcutaneous Implant with an Enzymatic Biosensor Based on Clinical Data.Biosensors · 2026Article
- Integrating Therapeutic Drug Monitoring and Metabolomics to Explore Interindividual Variability in Lamotrigine Response in Epilepsy.Drug design, development and therapy · 2026Article
- Tracking global quality of life trajectories in knee osteoarthritis: a population-based long-term analysis.Therapeutic advances in musculoskeletal disease · 2026Article
- TFFBN-HDLF: a hybrid deep learning framework based on time-frequency functional brain networks for epileptic seizure detection.Frontiers in medicine · 2026Article
- Global, regional, and national burden and trends of idiopathic epilepsy among children and adolescents from 1990 to 2021: insights from the global burden of disease study 2021.Annals of medicine · 2025Article
- Global burden, trends, and inequalities in cancer and subtypes attributable to high BMI among older adults, 1990-2021: a secondary analysis of the global burden of disease study 2021.Frontiers in nutrition · 2025Article
- China's epilepsy nurse training bases: construction needs indicators from a survey of 269 medical institutions.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEpilepsy among older populations has emerged as a growing global health concern in recent decades. However, comprehensive analyses of epilepsy burden among older adults are limited. This study aimed to assess the global burden of idiopathic epilepsy in the population aged 60 and above from 1990 to 2021 and project trends through 2035.
methodsUsing data from the Global Burden of Disease (GBD) study 2021, we analyzed epilepsy-related metrics including incidence, prevalence, mortality, and disability-adjusted life years (DALYs) across 204 countries and territories, stratified by age, sex, and Socio-demographic Index (SDI). Data analysis encompassed relative change calculations, as well as average annual percentage change (AAPC). Additionally, we performed a decomposition analysis to determine the contributions of population growth, aging, and epidemiological changes, and used Bayesian age-period-cohort (BAPC) modeling to project future burden through 2035.
resultsFrom 1990 to 2021, the global burden of idiopathic epilepsy in older adults increased substantially, with rises in age-standardized incidence (26.64%), prevalence (20.01%), mortality (4.45%), and DALYs (0.32%). Males consistently showed higher burden across metrics. Regional analysis revealed significant disparities, with Western Europe reporting the highest age-standardized incidence rate and Andean Latin America the highest prevalence rate in 2021. Higher SDI regions demonstrated better outcomes in mortality and DALYs, though showing unique increases in age-standardized rates. Population growth emerged as the primary driver of increased burden across regions. Projections through 2035 indicate continuing increases in incidence (AAPC: 1.64%) and prevalence (AAPC: 1.34%) rates, while mortality (AAPC: -1.29%) and DALY (AAPC: -0.12%) rates are expected to decline.
conclusionsThe global burden of idiopathic epilepsy in older adults has increased significantly, with notable disparities across regions and socioeconomic levels. While projected declines in mortality and DALY rates suggest improving healthcare outcomes, rising incidence and prevalence rates highlight the need for enhanced prevention strategies and specialized geriatric epilepsy care, particularly in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.